APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilars Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Biosimilars Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025199 pages

Choose your research edition.

Industry ResearchBiosimilars Drug Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilars Drug Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Biosimilars Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilars Drug Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilars Drug Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Biosimilars Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Biosimilars Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biosimilars Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biosimilars Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Biosimilars Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biosimilars Drug include Sanofi, Qilu Pharmaceutical, Novartis, Eli Lilly, Pfizer, Zhejiang Hisun, Wockhardt, United Laboratory and Tonghua Dongbao, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Biosimilars Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biosimilars Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilars Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Biosimilars Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Biosimilars Drug Segment by Company

Sanofi

Qilu Pharmaceutical

Novartis

Eli Lilly

Pfizer

Zhejiang Hisun

Wockhardt

United Laboratory

Tonghua Dongbao

Shanghai Henlius

Luye Pharma

Jiangsu Hengrui

Innovent Biologics

Geropharm

Gan&Lee

Dr Reddy’s

Celltrion

Celgen Biopharma

Bio-Thera

Biocon

3SBIO

Biosimilars Drug Segment by Type

Monoclonal Antibodies

Insulin

Others

Biosimilars Drug Segment by Application

Hospital

Retail Pharmacy

Other

Biosimilars Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilars Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilars Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilars Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Biosimilars Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biosimilars Drug industry.

Chapter 3: Detailed analysis of Biosimilars Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilars Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biosimilars Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Monoclonal Antibodies Table 3. Key Players of Insulin Table 4. Key Players of Others Table 4. Global Biosimilars Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Table 6. Key Players of Retail Pharmacy Table 7. Key Players of Other Table 8. Global Biosimilars Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Biosimilars Drug Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Biosimilars Drug Market Share by Region (2021-2026) Table 11. Global Biosimilars Drug Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Biosimilars Drug Market Share by Region (2027-2032) Table 13. Biosimilars Drug Industry Trends Table 14. Biosimilars Drug Industry Drivers Table 15. Biosimilars Drug Industry Opportunities and Challenges Table 16. Biosimilars Drug Industry Restraints Table 17. Global Biosimilars Drug Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Biosimilars Drug Revenue Market Share by Company (2021-2026) Table 19. Global Biosimilars Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Biosimilars Drug Key Company Head Office and Area Served Table 21. Global Biosimilars Drug Company, Product Type & Application Table 22. Global Biosimilars Drug Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Biosimilars Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Biosimilars Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Biosimilars Drug Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Biosimilars Drug Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Biosimilars Drug Revenue Market Share by Type (2021-2026) Table 29. Global Biosimilars Drug Revenue Market Share by Type (2027-2032) Table 30. Global Biosimilars Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Biosimilars Drug Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Biosimilars Drug Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Biosimilars Drug Revenue Market Share by Application (2021-2026) Table 34. Global Biosimilars Drug Revenue Market Share by Application (2027-2032) Table 35. Sanofi Company Information Table 36. Sanofi Business Overview Table 37. Sanofi Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Sanofi Biosimilars Drug Product Portfolio Table 39. Sanofi Recent Development Table 40. Qilu Pharmaceutical Company Information Table 41. Qilu Pharmaceutical Business Overview Table 42. Qilu Pharmaceutical Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Qilu Pharmaceutical Biosimilars Drug Product Portfolio Table 44. Qilu Pharmaceutical Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis Biosimilars Drug Product Portfolio Table 49. Novartis Recent Development Table 50. Eli Lilly Company Information Table 51. Eli Lilly Business Overview Table 52. Eli Lilly Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Eli Lilly Biosimilars Drug Product Portfolio Table 54. Eli Lilly Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Pfizer Biosimilars Drug Product Portfolio Table 59. Pfizer Recent Development Table 60. Zhejiang Hisun Company Information Table 61. Zhejiang Hisun Business Overview Table 62. Zhejiang Hisun Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Zhejiang Hisun Biosimilars Drug Product Portfolio Table 64. Zhejiang Hisun Recent Development Table 65. Wockhardt Company Information Table 66. Wockhardt Business Overview Table 67. Wockhardt Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Wockhardt Biosimilars Drug Product Portfolio Table 69. Wockhardt Recent Development Table 70. United Laboratory Company Information Table 71. United Laboratory Business Overview Table 72. United Laboratory Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. United Laboratory Biosimilars Drug Product Portfolio Table 74. United Laboratory Recent Development Table 75. Tonghua Dongbao Company Information Table 76. Tonghua Dongbao Business Overview Table 77. Tonghua Dongbao Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Tonghua Dongbao Biosimilars Drug Product Portfolio Table 79. Tonghua Dongbao Recent Development Table 80. Shanghai Henlius Company Information Table 81. Shanghai Henlius Business Overview Table 82. Shanghai Henlius Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Shanghai Henlius Biosimilars Drug Product Portfolio Table 84. Shanghai Henlius Recent Development Table 85. Luye Pharma Company Information Table 86. Luye Pharma Business Overview Table 87. Luye Pharma Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Luye Pharma Biosimilars Drug Product Portfolio Table 89. Luye Pharma Recent Development Table 90. Jiangsu Hengrui Company Information Table 91. Jiangsu Hengrui Business Overview Table 92. Jiangsu Hengrui Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. Jiangsu Hengrui Biosimilars Drug Product Portfolio Table 94. Jiangsu Hengrui Recent Development Table 95. Innovent Biologics Company Information Table 96. Innovent Biologics Business Overview Table 97. Innovent Biologics Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 98. Innovent Biologics Biosimilars Drug Product Portfolio Table 99. Innovent Biologics Recent Development Table 100. Geropharm Company Information Table 101. Geropharm Business Overview Table 102. Geropharm Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 103. Geropharm Biosimilars Drug Product Portfolio Table 104. Geropharm Recent Development Table 105. Gan&Lee Company Information Table 106. Gan&Lee Business Overview Table 107. Gan&Lee Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 108. Gan&Lee Biosimilars Drug Product Portfolio Table 109. Gan&Lee Recent Development Table 110. Dr Reddy’s Company Information Table 111. Dr Reddy’s Business Overview Table 112. Dr Reddy’s Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 113. Dr Reddy’s Biosimilars Drug Product Portfolio Table 114. Dr Reddy’s Recent Development Table 115. Celltrion Company Information Table 116. Celltrion Business Overview Table 117. Celltrion Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 118. Celltrion Biosimilars Drug Product Portfolio Table 119. Celltrion Recent Development Table 120. Celgen Biopharma Company Information Table 121. Celgen Biopharma Business Overview Table 122. Celgen Biopharma Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 123. Celgen Biopharma Biosimilars Drug Product Portfolio Table 124. Celgen Biopharma Recent Development Table 125. Bio-Thera Company Information Table 126. Bio-Thera Business Overview Table 127. Bio-Thera Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 128. Bio-Thera Biosimilars Drug Product Portfolio Table 129. Bio-Thera Recent Development Table 130. Biocon Company Information Table 131. Biocon Business Overview Table 132. Biocon Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 133. Biocon Biosimilars Drug Product Portfolio Table 134. Biocon Recent Development Table 135. 3SBIO Company Information Table 136. 3SBIO Business Overview Table 137. 3SBIO Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 138. 3SBIO Biosimilars Drug Product Portfolio Table 139. 3SBIO Recent Development Table 140. North America Biosimilars Drug Market Size by Type (2021-2026) & (US$ Million) Table 141. North America Biosimilars Drug Market Size by Type (2027-2032) & (US$ Million) Table 142. North America Biosimilars Drug Market Size by Application (2021-2026) & (US$ Million) Table 143. North America Biosimilars Drug Market Size by Application (2027-2032) & (US$ Million) Table 144. North America Biosimilars Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. North America Biosimilars Drug Market Size by Country (2021-2026) Table 146. North America Biosimilars Drug Market Size by Country (2027-2032) Table 147. Europe Biosimilars Drug Market Size by Type (2021-2026) & (US$ Million) Table 148. Europe Biosimilars Drug Market Size by Type (2027-2032) & (US$ Million) Table 149. Europe Biosimilars Drug Market Size by Application (2021-2026) & (US$ Million) Table 150. Europe Biosimilars Drug Market Size by Application (2027-2032) & (US$ Million) Table 151. Europe Biosimilars Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. Europe Biosimilars Drug Market Size by Country (2021-2026) Table 153. Europe Biosimilars Drug Market Size by Country (2027-2032) Table 154. China Biosimilars Drug Market Size by Type (2021-2026) & (US$ Million) Table 155. China Biosimilars Drug Market Size by Type (2027-2032) & (US$ Million) Table 156. China Biosimilars Drug Market Size by Application (2021-2026) & (US$ Million) Table 157. China Biosimilars Drug Market Size by Application (2027-2032) & (US$ Million) Table 158. Asia Biosimilars Drug Market Size by Type (2021-2026) & (US$ Million) Table 159. Asia Biosimilars Drug Market Size by Type (2027-2032) & (US$ Million) Table 160. Asia Biosimilars Drug Market Size by Application (2021-2026) & (US$ Million) Table 161. Asia Biosimilars Drug Market Size by Application (2027-2032) & (US$ Million) Table 162. Asia Biosimilars Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Asia Biosimilars Drug Market Size by Country (2021-2026) Table 164. Asia Biosimilars Drug Market Size by Country (2027-2032) Table 165. South America, Middle East & Africa Biosimilars Drug Market Size by Type (2021-2026) & (US$ Million) Table 166. South America, Middle East & Africa Biosimilars Drug Market Size by Type (2027-2032) & (US$ Million) Table 167. South America, Middle East & Africa Biosimilars Drug Market Size by Application (2021-2026) & (US$ Million) Table 168. South America, Middle East & Africa Biosimilars Drug Market Size by Application (2027-2032) & (US$ Million) Table 169. South America, Middle East & Africa Biosimilars Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. South America, Middle East & Africa Biosimilars Drug Market Size by Country (2021-2026) Table 171. South America, Middle East & Africa Biosimilars Drug Market Size by Country (2027-2032) Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Biosimilars Drug Product Image Figure 2. Global Biosimilars Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Biosimilars Drug Market Share by Type: 2025 VS 2032 Figure 4. Monoclonal Antibodies Image Figure 5. Insulin Image Figure 6. Others Image Figure 7. Global Biosimilars Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Biosimilars Drug Market Share by Application: 2025 VS 2032 Figure 9. Hospital Image Figure 10. Retail Pharmacy Image Figure 11. Other Image Figure 12. Global Biosimilars Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 14. Global Biosimilars Drug Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Biosimilars Drug Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Biosimilars Drug Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Biosimilars Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Biosimilars Drug Revenue Market Share by Type (2021-2032) Figure 21. Global Biosimilars Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Biosimilars Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 24. North America Biosimilars Drug Market Share by Type (2021-2032) Figure 25. North America Biosimilars Drug Market Share by Application (2021-2032) Figure 26. North America Biosimilars Drug Market Share by Country (2021-2032) Figure 27. United States Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 28. Canada Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 30. Europe Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 31. Europe Biosimilars Drug Market Share by Type (2021-2032) Figure 32. Europe Biosimilars Drug Market Share by Application (2021-2032) Figure 33. Europe Biosimilars Drug Market Share by Country (2021-2032) Figure 34. Germany Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 35. France Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 37. Italy Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 38. Russia Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 40. China Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 41. China Biosimilars Drug Market Share by Type (2021-2032) Figure 42. China Biosimilars Drug Market Share by Application (2021-2032) Figure 43. Asia Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 44. Asia Biosimilars Drug Market Share by Type (2021-2032) Figure 45. Asia Biosimilars Drug Market Share by Application (2021-2032) Figure 46. Asia Biosimilars Drug Market Share by Country (2021-2032) Figure 47. Japan Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 51. India Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 52. Australia Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Biosimilars Drug Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Biosimilars Drug Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Biosimilars Drug Market Share by Country (2021-2032) Figure 57. Brazil Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 62. UAE Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 64. Chile Biosimilars Drug Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Insulin
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Sanofi
  • Qilu Pharmaceutical
  • Novartis
  • Eli Lilly
  • Pfizer
  • Zhejiang Hisun
  • Wockhardt
  • United Laboratory
  • Tonghua Dongbao
  • Shanghai Henlius
  • Luye Pharma
  • Jiangsu Hengrui
  • Innovent Biologics
  • Geropharm
  • Gan&Lee
  • Dr Reddy’s
  • Celltrion
  • Celgen Biopharma
  • Bio-Thera
  • Biocon
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Biosimilars Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Monoclonal Antibodies
  5. 1.2.3 Insulin
  6. 1.2.4 Others
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Biosimilars Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Retail Pharmacy
  11. 1.3.4 Other
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Biosimilars Drug Growth Trends by Region
  14. 1.5.1 Global Biosimilars Drug Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Biosimilars Drug Market Size by Region (2021-2026)
  16. 1.5.3 Biosimilars Drug Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Biosimilars Drug Market Dynamics
  1. 2.1 Biosimilars Drug Industry Trends
  2. 2.2 Biosimilars Drug Industry Drivers
  3. 2.3 Biosimilars Drug Industry Opportunities and Challenges
  4. 2.4 Biosimilars Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Biosimilars Drug Revenue by Company (2021-2026)
  2. 3.2 Global Biosimilars Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Biosimilars Drug Key Company Head office and Area Served
  4. 3.4 Global Biosimilars Drug Company, Product Type & Application
  5. 3.5 Global Biosimilars Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Biosimilars Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Biosimilars Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Biosimilars Drug Tier 1, Tier 2, and Tier 3
4 Biosimilars Drug Market by Type
  1. 4.1 Global Biosimilars Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Biosimilars Drug Market Size by Type (2021-2032)
  3. 4.3 Global Biosimilars Drug Market Size Share by Type (2021-2032)
5 Biosimilars Drug Market by Application
  1. 5.1 Global Biosimilars Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Biosimilars Drug Market Size by Application (2021-2032)
  3. 5.3 Global Biosimilars Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sanofi Biosimilars Drug Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Qilu Pharmaceutical
  8. 6.2.1 Qilu Pharmaceutical Company Information
  9. 6.2.2 Qilu Pharmaceutical Business Overview
  10. 6.2.3 Qilu Pharmaceutical Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Qilu Pharmaceutical Biosimilars Drug Product Portfolio
  12. 6.2.5 Qilu Pharmaceutical Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Novartis Biosimilars Drug Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Eli Lilly
  20. 6.4.1 Eli Lilly Company Information
  21. 6.4.2 Eli Lilly Business Overview
  22. 6.4.3 Eli Lilly Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Eli Lilly Biosimilars Drug Product Portfolio
  24. 6.4.5 Eli Lilly Recent Developments
  25. 6.5 Pfizer
  26. 6.5.1 Pfizer Company Information
  27. 6.5.2 Pfizer Business Overview
  28. 6.5.3 Pfizer Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Pfizer Biosimilars Drug Product Portfolio
  30. 6.5.5 Pfizer Recent Developments
  31. 6.6 Zhejiang Hisun
  32. 6.6.1 Zhejiang Hisun Company Information
  33. 6.6.2 Zhejiang Hisun Business Overview
  34. 6.6.3 Zhejiang Hisun Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Zhejiang Hisun Biosimilars Drug Product Portfolio
  36. 6.6.5 Zhejiang Hisun Recent Developments
  37. 6.7 Wockhardt
  38. 6.7.1 Wockhardt Company Information
  39. 6.7.2 Wockhardt Business Overview
  40. 6.7.3 Wockhardt Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Wockhardt Biosimilars Drug Product Portfolio
  42. 6.7.5 Wockhardt Recent Developments
  43. 6.8 United Laboratory
  44. 6.8.1 United Laboratory Company Information
  45. 6.8.2 United Laboratory Business Overview
  46. 6.8.3 United Laboratory Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 United Laboratory Biosimilars Drug Product Portfolio
  48. 6.8.5 United Laboratory Recent Developments
  49. 6.9 Tonghua Dongbao
  50. 6.9.1 Tonghua Dongbao Company Information
  51. 6.9.2 Tonghua Dongbao Business Overview
  52. 6.9.3 Tonghua Dongbao Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Tonghua Dongbao Biosimilars Drug Product Portfolio
  54. 6.9.5 Tonghua Dongbao Recent Developments
  55. 6.10 Shanghai Henlius
  56. 6.10.1 Shanghai Henlius Company Information
  57. 6.10.2 Shanghai Henlius Business Overview
  58. 6.10.3 Shanghai Henlius Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Shanghai Henlius Biosimilars Drug Product Portfolio
  60. 6.10.5 Shanghai Henlius Recent Developments
  61. 6.11 Luye Pharma
  62. 6.11.1 Luye Pharma Company Information
  63. 6.11.2 Luye Pharma Business Overview
  64. 6.11.3 Luye Pharma Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Luye Pharma Biosimilars Drug Product Portfolio
  66. 6.11.5 Luye Pharma Recent Developments
  67. 6.12 Jiangsu Hengrui
  68. 6.12.1 Jiangsu Hengrui Company Information
  69. 6.12.2 Jiangsu Hengrui Business Overview
  70. 6.12.3 Jiangsu Hengrui Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Jiangsu Hengrui Biosimilars Drug Product Portfolio
  72. 6.12.5 Jiangsu Hengrui Recent Developments
  73. 6.13 Innovent Biologics
  74. 6.13.1 Innovent Biologics Company Information
  75. 6.13.2 Innovent Biologics Business Overview
  76. 6.13.3 Innovent Biologics Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Innovent Biologics Biosimilars Drug Product Portfolio
  78. 6.13.5 Innovent Biologics Recent Developments
  79. 6.14 Geropharm
  80. 6.14.1 Geropharm Company Information
  81. 6.14.2 Geropharm Business Overview
  82. 6.14.3 Geropharm Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Geropharm Biosimilars Drug Product Portfolio
  84. 6.14.5 Geropharm Recent Developments
  85. 6.15 Gan&Lee
  86. 6.15.1 Gan&Lee Company Information
  87. 6.15.2 Gan&Lee Business Overview
  88. 6.15.3 Gan&Lee Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Gan&Lee Biosimilars Drug Product Portfolio
  90. 6.15.5 Gan&Lee Recent Developments
  91. 6.16 Dr Reddy’s
  92. 6.16.1 Dr Reddy’s Company Information
  93. 6.16.2 Dr Reddy’s Business Overview
  94. 6.16.3 Dr Reddy’s Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Dr Reddy’s Biosimilars Drug Product Portfolio
  96. 6.16.5 Dr Reddy’s Recent Developments
  97. 6.17 Celltrion
  98. 6.17.1 Celltrion Company Information
  99. 6.17.2 Celltrion Business Overview
  100. 6.17.3 Celltrion Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Celltrion Biosimilars Drug Product Portfolio
  102. 6.17.5 Celltrion Recent Developments
  103. 6.18 Celgen Biopharma
  104. 6.18.1 Celgen Biopharma Company Information
  105. 6.18.2 Celgen Biopharma Business Overview
  106. 6.18.3 Celgen Biopharma Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Celgen Biopharma Biosimilars Drug Product Portfolio
  108. 6.18.5 Celgen Biopharma Recent Developments
  109. 6.19 Bio-Thera
  110. 6.19.1 Bio-Thera Company Information
  111. 6.19.2 Bio-Thera Business Overview
  112. 6.19.3 Bio-Thera Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Bio-Thera Biosimilars Drug Product Portfolio
  114. 6.19.5 Bio-Thera Recent Developments
  115. 6.20 Biocon
  116. 6.20.1 Biocon Company Information
  117. 6.20.2 Biocon Business Overview
  118. 6.20.3 Biocon Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Biocon Biosimilars Drug Product Portfolio
  120. 6.20.5 Biocon Recent Developments
  121. 6.21 3SBIO
  122. 6.21.1 3SBIO Company Information
  123. 6.21.2 3SBIO Business Overview
  124. 6.21.3 3SBIO Biosimilars Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  125. 6.21.4 3SBIO Biosimilars Drug Product Portfolio
  126. 6.21.5 3SBIO Recent Developments
7 North America
  1. 7.1 North America Biosimilars Drug Market Size (2021-2032)
  2. 7.2 North America Biosimilars Drug Market Size by Type
  3. 7.2.1 North America Biosimilars Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Biosimilars Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Biosimilars Drug Market Share by Type (2021-2032)
  6. 7.3 North America Biosimilars Drug Market Size by Application
  7. 7.3.1 North America Biosimilars Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Biosimilars Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Biosimilars Drug Market Share by Application (2021-2032)
  10. 7.4 North America Biosimilars Drug Market Size by Country
  11. 7.4.1 North America Biosimilars Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Biosimilars Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Biosimilars Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Biosimilars Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Biosimilars Drug Market Size (2021-2032)
  2. 8.2 Europe Biosimilars Drug Market Size by Type
  3. 8.2.1 Europe Biosimilars Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Biosimilars Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Biosimilars Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Biosimilars Drug Market Size by Application
  7. 8.3.1 Europe Biosimilars Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Biosimilars Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Biosimilars Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Biosimilars Drug Market Size by Country
  11. 8.4.1 Europe Biosimilars Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Biosimilars Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Biosimilars Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Biosimilars Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Biosimilars Drug Market Size (2021-2032)
  2. 9.2 China Biosimilars Drug Market Size by Type
  3. 9.2.1 China Biosimilars Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Biosimilars Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Biosimilars Drug Market Share by Type (2021-2032)
  6. 9.3 China Biosimilars Drug Market Size by Application
  7. 9.3.1 China Biosimilars Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Biosimilars Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Biosimilars Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Biosimilars Drug Market Size (2021-2032)
  2. 10.2 Asia Biosimilars Drug Market Size by Type
  3. 10.2.1 Asia Biosimilars Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Biosimilars Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Biosimilars Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Biosimilars Drug Market Size by Application
  7. 10.3.1 Asia Biosimilars Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Biosimilars Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Biosimilars Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Biosimilars Drug Market Size by Country
  11. 10.4.1 Asia Biosimilars Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Biosimilars Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Biosimilars Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Biosimilars Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Biosimilars Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Biosimilars Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Biosimilars Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Biosimilars Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Biosimilars Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Biosimilars Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Biosimilars Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Biosimilars Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Biosimilars Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Biosimilars Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Biosimilars Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Biosimilars Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Biosimilars Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Biosimilars Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst